Medical Advocates
HAART/ART
  Cardiovascular Adverse Events
General Reports 
Atherosclerosis
 Cardiomyopathy 
 Carotid Artery Disorders
Cholesterol levels Increases   
Hypertension
 Lipid Disorders
Myocardial Infarction


 		  
HAART Adverse Events Main New/Newsworthy Home Page
Last Update:  November 18, 2008  
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
                    

          Journal Papers, Abstracts, and Commentaries

 
Silent cardiac dysfunction and exercise intolerance in HIV+ men receiving combined antiretroviral therapies.
Thöni GJ, Schuster I, Walther G, et al
AIDS. 2008 Nov 30;22(18):2537-2540
 Abstract
 
HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in
HIV-infected patients.
 Kotler DP.
 J Acquir Immune Defic Syndr. 2008 Sep 1;49 Suppl 2:S79-85.
 Abstract
 
Ankle-branch index and HIV: the role of antiretrovirals.
Olalla J, Salas D, Del Arco A, et al
HIV Med. 2008 Sep 14.
Abstract
 
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and
after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Torriani FJ, Komarow L, Parker RA, et al
J Am Coll Cardiol. 2008 Aug 12;52(7):569-76.
 Abstract
 
HIV Therapy, Metabolic Syndrome, and Cardiovascular Risk.
Pao V, Lee GA, Grunfeld C. et al
Curr Atheroscler Rep. 2008 Feb;10(1):61-70
 Abstract
 
Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection
and antiretroviral therapy.
Calza L, Manfredi R, Pocaterra D, Chiodo F.
J Infect. 2008 Mar 19
Abstract
 
Dyslipidemia and Cardiovascular Disease Risk Factor Management in HIV-1-Infected Subjects Treated with HAART in the
Spanish VACH Cohort.
Pere D, Ignacio SL, Ramón T,
Open AIDS J. 2008;2:26-38.
 Abstract
 
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of
antiretroviral therapy in HIV infection.
Wand H, Calmy A, Carey DL, Samaras K, et al 
AIDS. 2007 Nov 30;21(18):2445-2453.
Abstract
 
Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate
variability.
Lebech AM, Kristoffersen US, Mehlsen J, et al 
Clin Physiol Funct Imaging. 2007 Nov;27(6):363-7.
Abstract

Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and
cardiovascular risk
Barbaro G.Am J Ther. 2006 May-Jun;13(3):248-60.
Abstract

Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome and Cardiovascular Risk.
Barbaro G, Barbarini G.
 Chemotherapy. 2006 May 2;52(4):161-165
 Abstract
 
HAART to Heart: HIV-related Cardiomyopathy and Other Cardiovascular Complications.
 Dakin CL, O’connor CA, Patsdaughter CA. 
AACN Clin Issues. 2006 January/March;17(1):18-29.
Abstract
 
Age and sex modulate metabolic and cardiovascular risk markers of patients after 1 year of
highly active antiretroviral therapy (HAART).
 Leitner JM, Pernerstorfer-Schoen H,
 Atherosclerosis. 2005 Oct 1;
 Abstract
 
Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of
Highly Active Antiretroviral Therapy.
Barbaro G.
Curr Drug Targets Cardiovasc Haematol Disord. 2005 Aug;5(4):337-43.
 Abstract
 
Coronary Artery Calcium in HIV-infected Men Treated With Highly Active Antiretroviral Therapy.
Robinson FP, Hoff JA, Kondos GT. 
J Cardiovasc Nurs. 2005 May/June;20(3):149-154.
Abstract
 
Antiretroviral therapy and cardiovascular risk.
 Vandhuick O, Guias B, De Saint Martin L, Bressollette L.
J Mal Vasc. 2004 Oct;29(4):192-199
 Abstract
 
Risks of cardiovascular disease in patients receiving antiretroviral therapy for
HIV infection: implications for treatment.
Steinhart CR, Emons MF
AIDS Read. 2004 Feb;14(2):86-90, 93-5
 Abstract

Combination antiretroviral therapy and the risk of myocardial infarction.
Friis-Moller N, Sabin CA, Weber R, et al
N Engl J Med. 2003 Nov 20;349(21):1993-2003.
Abstract
 
       Conference Reports, Abstracts, and Posters
 
 
A large prospective cohort study of cardiovascular risk and associated
metabolic changes in HIV infection: CREATE 1 (cardiovascular risk evaluation
and antiretroviral therapy)
 Aboud M, Elgalib A, Pomeroy L
(4th IAS Conference)
 Abstract

Cerebro- and cardiovascular events and cardiovascular mortality in HIV-infected patients
were significantly increased after the introduction of HAART
P Freitas, D Carvalho, T Costa, et al
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract

Atherosclerosis
                    
          Journal Papers, Abstracts, and Commentaries
 
 
Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection
and antiretroviral therapy.
Calza L, Manfredi R, Pocaterra D, Chiodo F.
J Infect. 2008 Mar 19
Abstract

Premature atherosclerosis in HIV positive patients and cumulated time of exposure
to antiretroviral therapy (SHIVA study).
Martin LD, Vandhuick O, Guillo P, et al 
Atherosclerosis. 2005 Aug 29;
Abstract

Comparison of the risks of atherosclerotic events versus death from other causes associated
with antiretroviral use.
 Kwong GP, Ghani AC, Rode RA, et al
 AIDS. 2006 Oct 3;20(15):1941-1950.
Abstract

       Conference Reports, Abstracts, and Posters

  Predictors of Atherosclerosis as Measured by Carotid Intima-Media Thickness in
Non-Smoking HIV Patients
A. LEBECH, N. WIINBERG , J. GERSTOFT ,  et al
 (45 ICAAC)
 Abstract

Cardiomyopathy
                    

          Journal Papers, Abstracts, and Commentaries

 
HAART to Heart: HIV-related Cardiomyopathy and Other Cardiovascular Complications.
Dakin CL, O’connor CA, Patsdaughter CA. 
AACN Clin Issues. 2006 January/March;17(1):18-29.
 Abstract

Dilated Cardiomyopathy in Two Adult Human Immunodeficiency Positive (HIV+) Patients Possibly
Related to Highly Active Antiretroviral Therapy (HAART).
Breuckmann F, Neumann T, Kondratieva J, et al 
Eur J Med Res. 2005 Sep 12;10(9):395-9.
Abstract

Carotid Artery Disorders
                    

          Conference Reports, Abstracts, and Posters

  3-year Follow-up of Carotid Intima-media Thickness in HIV-infected and Uninfected
Adults: ACTG 5078
J Currier, M Kendall, K Henry, et al
(13 CROI)
 Abstract

Cholesterol Levels Increases
                    

          Journal Papers, Abstracts, and Commentaries

  Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral
therapy.
Anuurad E, Thomas-Geevarghese A, Devaraj S, et al
 Atherosclerosis. 2007 Nov 8
 Abstract
Hypertension
                    

          Journal Papers, Abstracts, and Commentaries
 
 
Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients.
A prospective study in a cohort of naive patients.
Palacios R, Santos J, Garcia A, et al 
HIV Med. 2006 Jan;7(1):10-5.
Abstract
 
Association between highly active antiretroviral therapy and hypertension in a large
cohort of men followed from 1984 to 2003.
Seaberg EC, Munoz A, Lu M, et al 
AIDS. 2005 Jun 10;19(9):953-960.
 Abstract

Regression of HIV-associated pulmonary arterial hypertension and
long-term survival during antiretroviral therapy.
 Speich R, Jenni R, Opravil M, Jaccard R.
 Swiss Med Wkly 2001 Dec 1;131(45-46):663-5
Abstract

  
          Conference Reports, Abstracts, and Posters

  HIV-associated Pulmonary Hypertension in Patients on HAART
 S Rosenkranz, H Steffen, D Vogel, et al
(12 CROI)
Abstract  
 
The Association between Increasing Blood Pressure and Use of NNRTI and
Lopinavir/Ritonavir
 H Crane, S Van Rompaey, M Kitahata
(12 CROI)
Abstract  
 
The Effect of HAART Initiation on Blood Pressure
 E  Seaberg , S Riddler, J Margolick, et al
(12 CROI)
Abstract  
Myocardial Infarction
                    

          Conference Reports, Abstracts, and Posters

  Exposure to PI and NNRTI and Risk of Myocardial Infarction: Results from the D:A:D Study
N Friis-Møller, P Reis, W El-Sadr, et al
 (13 CROI)
 Abstract

HAART Adverse Events Main New/Newsworthy Home Page

HAART/ART Adverse Cardiovascular Events